Literature DB >> 9681419

Adenovirus-mediated gene transfer to lower limb artery of patients with chronic critical leg ischemia.

M Laitinen1, K Mäkinen, H Manninen, P Matsi, M Kossila, R S Agrawal, T Pakkanen, J S Luoma, H Viita, J Hartikainen, E Alhava, M Laakso, S Ylä-Herttuala.   

Abstract

Arterial gene transfer offers a promising new approach for the treatment of vascular disorders. However, no data are available about the gene transfer efficiency in human arteries in vivo. The aim of this study was to evaluate the safety and feasibility of catheter-mediated adenoviral gene transfer in human peripheral arteries. Ten patients (8 females, 2 males, mean age 80 +/- 8 years) suffering from chronic critical leg ischemia with a prior decision for amputation were recruited in the study. Gene transfer was performed in eight patients in conjunction with a conventional percutaneous transluminal angioplasty, using a perfusion coil balloon catheter. Two patients served as controls. Increasing concentrations of replication-deficient adenoviruses (titers from 1 x 10(8) to 4 x 10(10) PFU) containing a nuclear-targeted beta-galactosidase marker gene were administered into the arteries over 10 min via the catheter. Amputations were performed 20 to 51 hr after the procedures and gene transfer efficiency was evaluated in the transduced arteries using X-Gal staining for beta-galactosidase activity. Beta-galactosidase gene transfer was well tolerated and no adverse tissue responses or systemic complications were observed in any of the patients. Gene transfer was successful in six of the eight patients. Gene transfer efficiency varied between 0.04 and 5.0% of all arterial cells. Transgene expression was detected in smooth muscle cells, endothelial cells, and macrophages and in tunica adventitia. However, transgene activity was not evenly distributed in the arterial wall and no transgene activity was found beneath advanced atherosclerotic lesions. The safety and feasibility of in vivo gene transfer by adenoviral vectors to human peripheral arteries were established. Although improvements are still required in gene transfer efficiency, these findings suggest that adenoviruses can be used to deliver therapeutically active genes into human arteries.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9681419     DOI: 10.1089/hum.1998.9.10-1481

Source DB:  PubMed          Journal:  Hum Gene Ther        ISSN: 1043-0342            Impact factor:   5.695


  27 in total

Review 1.  Clinical applications of vascular gene therapy.

Authors:  J Rutanen; T T Rissanen; A Kivelä; I Vajanto; S Ylä-Herttuala
Journal:  Curr Cardiol Rep       Date:  2001-01       Impact factor: 2.931

2.  Adeno-associated viral vector-mediated vascular endothelial growth factor gene transfer induces neovascular formation in ischemic heart.

Authors:  H Su; R Lu; Y W Kan
Journal:  Proc Natl Acad Sci U S A       Date:  2000-12-05       Impact factor: 11.205

3.  Lymphatic endothelial reprogramming of vascular endothelial cells by the Prox-1 homeobox transcription factor.

Authors:  Tatiana V Petrova; Taija Mäkinen; Tomi P Mäkelä; Janna Saarela; Ismo Virtanen; Robert E Ferrell; David N Finegold; Dontscho Kerjaschki; Seppo Ylä-Herttuala; Kari Alitalo
Journal:  EMBO J       Date:  2002-09-02       Impact factor: 11.598

4.  Phosphorylation regulates FOXC2-mediated transcription in lymphatic endothelial cells.

Authors:  Konstantin I Ivanov; Yan Agalarov; Leena Valmu; Olga Samuilova; Johanna Liebl; Nawal Houhou; Hélène Maby-El Hajjami; Camilla Norrmén; Muriel Jaquet; Naoyuki Miura; Nadine Zangger; Seppo Ylä-Herttuala; Mauro Delorenzi; Tatiana V Petrova
Journal:  Mol Cell Biol       Date:  2013-07-22       Impact factor: 4.272

Review 5.  Angiogenic gene therapy in cardiovascular diseases: dream or vision?

Authors:  Seppo Ylä-Herttuala; Charles Bridges; Michael G Katz; Petra Korpisalo
Journal:  Eur Heart J       Date:  2017-05-07       Impact factor: 29.983

6.  Vascular endothelial growth factor-C accelerates diabetic wound healing.

Authors:  Anne Saaristo; Tuomas Tammela; Anniina Farkkilā; Marika Kärkkäinen; Erkki Suominen; Seppo Yla-Herttuala; Kari Alitalo
Journal:  Am J Pathol       Date:  2006-09       Impact factor: 4.307

7.  Stabilization of HIF-1alpha is critical to improve wound healing in diabetic mice.

Authors:  Ileana Ruxandra Botusan; Vivekananda Gupta Sunkari; Octavian Savu; Anca Irinel Catrina; Jacob Grünler; Stina Lindberg; Teresa Pereira; Seppo Ylä-Herttuala; Lorenz Poellinger; Kerstin Brismar; Sergiu-Bogdan Catrina
Journal:  Proc Natl Acad Sci U S A       Date:  2008-12-04       Impact factor: 11.205

8.  Antiangiogenic gene therapy with soluble VEGFR-1, -2, and -3 reduces the growth of solid human ovarian carcinoma in mice.

Authors:  Hanna Sallinen; Maarit Anttila; Johanna Narvainen; Jonna Koponen; Kirsi Hamalainen; Ivana Kholova; Tommi Heikura; Pyry Toivanen; Veli-Matti Kosma; Seppo Heinonen; Kari Alitalo; Seppo Yla-Herttuala
Journal:  Mol Ther       Date:  2008-12-02       Impact factor: 11.454

Review 9.  Gene therapy for restenosis: current status.

Authors:  Juha Rutanen; Johanna Markkanen; Seppo Ylä-Herttuala
Journal:  Drugs       Date:  2002       Impact factor: 9.546

10.  FOXC2 controls formation and maturation of lymphatic collecting vessels through cooperation with NFATc1.

Authors:  Camilla Norrmén; Konstantin I Ivanov; Jianpin Cheng; Nadine Zangger; Mauro Delorenzi; Muriel Jaquet; Naoyuki Miura; Pauli Puolakkainen; Valerie Horsley; Junhao Hu; Hellmut G Augustin; Seppo Ylä-Herttuala; Kari Alitalo; Tatiana V Petrova
Journal:  J Cell Biol       Date:  2009-04-27       Impact factor: 10.539

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.